Alcresta, a Newton, MA-based medical nutrition company developing innovative enzyme-based products for adults, infants, and individuals battling acute conditions or chronic diseases, raised $10m in Series B financing.
The round was led by existing investors Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures.
The company intends to use the funds to advance regulatory filings, commercial planning and preparations for the expected 2014 launch of its lead nutritional product.
Co-founded by president Robert Gallotto and chief executive officer Alexey Margolin, Ph.D., Alcresta is developing novel nutritional products that can be used in conjunction with current standards of nutritional care to effectively maximize nutrient and caloric absorption. The company’s lead program is a point-of-care enzyme-based product focused on improving the digestion and enabling proper absorption of critically important good fats, in particular long-chain polyunsaturated fatty acids (LCPUFAs) like DHA, EPA and AA. Initially, it is focused on providing this product to individuals who require special nutritional care where there is a known relationship between proper nutrition, caloric intake and weight maintenance.